BiotechTube
Silver Lake Research

Silver Lake Research

Azusa, United States· Est.
silverlakeresearch.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Silver Lake Research is a long-established, privately-held diagnostics company specializing in lateral flow rapid tests powered by its proprietary EAP™ monoclonal antibody platform. The company has a commercial portfolio targeting areas like hemoglobinopathy screening (HemoTypeSC), water safety, and urinary tract infection detection (RapidBac™), and offers significant contract development and manufacturing (CDMO) services. With over 150 products marketed and 15 million+ test strips sold, Silver Lake leverages its integrated US-based capabilities for both its own branded products and private-label/contract manufacturing for partners. Its strategy is built on the unique specificity of its antibodies, turnkey manufacturing solutions, and a focus on point-of-care diagnostics.

HematologyInfectious DiseaseEnvironmental Health

Technology Platform

Proprietary EAP™ System (Epitope Amplification Process) for generating highly specific monoclonal antibodies that enable high-sensitivity lateral flow assays.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

Significant growth opportunity exists in the global rollout of HemoTypeSC for sickle cell screening in high-prevalence, low-resource regions, potentially supported by WHO initiatives.
The large and routine UTI testing market presents a major commercial target for RapidBac if it can displace culture-based methods.
The growing demand for outsourced development and manufacturing (CDMO) in diagnostics provides a scalable, diversified revenue stream leveraging the company's unique platform and US facility.

Risk Factors

Key risks include intense competition in both the hemoglobinopathy and UTI rapid test markets, requiring continuous demonstration of superior clinical utility and cost-effectiveness.
The business model relies on successful commercialization of its lead proprietary products; slower-than-expected adoption would impact growth.
As a CDMO, the company faces client concentration and project pipeline volatility risks.

Competitive Landscape

Silver Lake competes in the crowded lateral flow diagnostics market. For sickle cell tests, competitors include laboratory-based methods (HPLC, electrophoresis) and other POC tests like SickleScan. In UTI testing, it competes with dipsticks, other rapid tests, and automated urinalysis systems from major IVD companies. Its primary differentiation is the claimed superior performance derived from its EAP™ antibody platform, combined with full vertical integration and US manufacturing.

More companies in Diagnostics & Precision Medicine →More companies in United States →